Stifel stays Buy rated on X4 Pharmaceuticals (XFOR) as mavorixafor ph3 trial remains on-track

March 17, 2026 10:12 AM

Stifel analyst James Condulis reiterated a Buy rating and $10.00 price target on X4 Pharmaceuticals (NASDAQ: XFOR)The analyst commented, "We're ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found